Human Breast Cancer Anti-Estrogen Resistance 3 (BCAR3) Protein

Background

BCAR3, also known as Breast Cancer Anti-Estrogen Resistance Protein 3, is involved in the development of resistance to anti-estrogen therapies in breast cancer, much like its family members BCAR1 and BCAR2. BCAR3 has been shown to participate in signaling pathways that affect cell survival and migration. This protein is often implicated in the progression of cancer cells from an estrogen-dependent to an estrogen-independent state, allowing them to proliferate and survive despite the presence of estrogen inhibitors. BCAR3’s interaction with other molecular players in cell signaling, such as those controlling cytoskeletal reorganization, further contributes to cancer cell invasion and metastasis. Targeting BCAR3 may offer new therapeutic approaches for overcoming resistance in estrogen receptor-positive breast cancer, providing more effective treatments for patients with advanced disease. Its role in cancer progression and therapy resistance makes BCAR3 an important subject of ongoing research in oncology.